Peritoneal carcinomatosis is an advanced stage manifestation of several gynecologic and gastrointestinal malignancies with a median survival estimate of 2–5 months. Clinical data estimate that ovarian cancer, followed by colon cancer are the most common causes of this devastating disease, with peritoneal dissemination being diagnosed as the final step of this incurable cancer.
Current standard of care is cytoreductive surgery (peritonectomy), combined with intraperitoneal chemotherapy (hyperthermic intraperitoneal chemotherapy or intraportal adjuvant chemotherapy). However, these conventional treatments fail to show acceptable results in controlling the disease and improving overall survival. Consequently, peritoneal carcinomatosis is a disease with an urgent need for more effective treatment and a better understanding of the peritoneal cavity.
This Research Topic aims to address the recent approaches, advances, and characterization of peritoneal cancers, contributing to a better understanding of the peritoneal microenvironment. This will in turn aid in the determination of the most appropriate therapeutic interventions to improve patient outcomes from peritoneal carcinomatosis.
Authors are welcome to submit Original Research, Mini-Review, Review, Methods, Opinion, and Hypothesis & Theory articles that seek to understand the peritoneal tumor microenvironment and the effects of cancer treatments such as chemotherapy, radiotherapy and immunotherapy (single or in combination). Contributions investigating peritoneal immune populations, tumor microenvironment, peritoneal implants, exosomes in the ascites, predictive biomarkers, as well as novel experimental peritoneal carcinomatosis models, are also welcome.
The below will be considered:
• New findings in the peritoneal microenvironment relating to predictive biomarkers or targets.
• New advances in the treatments of peritoneal carcinomatosis.
• Preclinical peritoneal carcinomatosis models to develop and test new antitumor or immunomodulatory agents.
• Characterization of the tumor microenvironment in the peritoneum (ascites, omentum, mesenteric lymph nodes, etc.)
• Peritoneal immunobiology and implications in the development of peritoneal carcinomatosis.
Dr. Eduardo Huarte is an employee and shareholder of Incyte corporation. Dr. Javier Dotor is CSO, co-founder and shareholder of DISITBiotech S.L. invested by TAUPE Empresarial SL. No further commercial or financial relationships that could be construed as a potential conflict of interest are present.
Peritoneal carcinomatosis is an advanced stage manifestation of several gynecologic and gastrointestinal malignancies with a median survival estimate of 2–5 months. Clinical data estimate that ovarian cancer, followed by colon cancer are the most common causes of this devastating disease, with peritoneal dissemination being diagnosed as the final step of this incurable cancer.
Current standard of care is cytoreductive surgery (peritonectomy), combined with intraperitoneal chemotherapy (hyperthermic intraperitoneal chemotherapy or intraportal adjuvant chemotherapy). However, these conventional treatments fail to show acceptable results in controlling the disease and improving overall survival. Consequently, peritoneal carcinomatosis is a disease with an urgent need for more effective treatment and a better understanding of the peritoneal cavity.
This Research Topic aims to address the recent approaches, advances, and characterization of peritoneal cancers, contributing to a better understanding of the peritoneal microenvironment. This will in turn aid in the determination of the most appropriate therapeutic interventions to improve patient outcomes from peritoneal carcinomatosis.
Authors are welcome to submit Original Research, Mini-Review, Review, Methods, Opinion, and Hypothesis & Theory articles that seek to understand the peritoneal tumor microenvironment and the effects of cancer treatments such as chemotherapy, radiotherapy and immunotherapy (single or in combination). Contributions investigating peritoneal immune populations, tumor microenvironment, peritoneal implants, exosomes in the ascites, predictive biomarkers, as well as novel experimental peritoneal carcinomatosis models, are also welcome.
The below will be considered:
• New findings in the peritoneal microenvironment relating to predictive biomarkers or targets.
• New advances in the treatments of peritoneal carcinomatosis.
• Preclinical peritoneal carcinomatosis models to develop and test new antitumor or immunomodulatory agents.
• Characterization of the tumor microenvironment in the peritoneum (ascites, omentum, mesenteric lymph nodes, etc.)
• Peritoneal immunobiology and implications in the development of peritoneal carcinomatosis.
Dr. Eduardo Huarte is an employee and shareholder of Incyte corporation. Dr. Javier Dotor is CSO, co-founder and shareholder of DISITBiotech S.L. invested by TAUPE Empresarial SL. No further commercial or financial relationships that could be construed as a potential conflict of interest are present.